# Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia

> **NCT00148590** · PHASE3 · TERMINATED · sponsor: **M. Schaefer, MD** · enrollment: 24 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Memantine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00148590
- **Lead sponsor:** M. Schaefer, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148590, "Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00148590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*